.png){kind=icon}
Driving global success in infectious disease prevention and treatment
The continued rise in difficult-to-treat infections and deaths caused by multidrug-resistant pathogens, as well as COVID-19 and its variants, reinforces the need to develop more safe, robust and effective therapies and vaccines against emerging and re-emerging diseases to protect people across the globe—particularly for those who have inadequate access to medical care.
Our infectious disease and vaccine experts are among the more experienced and talented in the industry with expertise spanning nonclinical and clinical development of products to prevent and treat bacterial, viral, fungal and parasitic infections. In fact, we've worked on well over 160 infectious disease and vaccine studies within the past five years-including COVID-19-and leverage this expertise to shape new opportunities for you.
Decoding the complex challenges of vaccine and anti-infective drug development
From selecting the most appropriate animal model system to acquiring information on the immunogenicity of vaccine antigens to determining characteristics critical to your vaccine's success, we make sure your molecule regulatory submission is sound. 総合研究所と微生物学的サービスを利用した大規模なグローバル治験プロジェクトを早急に開始する必要がおありの場合は。当社の有する専門知識を用い、お客様の重要なマイルストーンを速やかに実現することができます。
特徴が明確な感染攻撃剤の検証済み系統を確保し、予防ワクチンや治療ワクチン、抗感染薬を検査
Capitalize on our significant BSL-1 and BSL-2 containment facilities, which are accredited by the American Association for Laboratory Animal Care, registered by the United States Department of Agriculture and assured by the Office of Laboratory Animal Welfare
Develop transport solutions and prepare custom minimal inhibitory concentration plates to test susceptibility for a new study drug
Attacking opportunistic pathogens using insight and expertise
世界的に見ると、尿路、創傷、血流の感染症や性感染症といった一般的な感染症に対する効果的な治療法が入手しにくくなってきていますが、こうした感染症は、感染リスクの高い集団や医療を利用する機会に恵まれない人々にとって、命にかかわることが少なくありません。 Similarly, emerging and re-emerging infectious diseases such as COVID-19 (SARS-CoV-2) and tuberculosis continue to pose a global public health threat. 研究の急速な発展と、疾病の予防や医療に関する新しい理論的枠組みの登場によって、新しいワクチンや治療法の開発競争は激化しており、その有効性を医学的および経済的に証明するための速やかな検証が求められています。 We have successfully partnered with biopharmaceutical companies to bring multiple assets to market including three of the last four antibiotics, as well as vaccines against COVID-19. ゲノム科学から、臨床開発、当社のセントラルラボにおける安全性およびウイルス性テストまで、当社はお客様の支援に尽力し、Solutions Made Real を実現します。
Comprehensive and integrated solutions to accelerate the development of your asset while maximizing your return on investment
We deliver a holistic suite of services, tools and technologies essential to infectious disease vaccine and therapy development. From preclinical immunology to proof-of-concept studies to larger Phase II/III clinical trials and post-approval studies, our goal is to draw on our vast scientific and operational experience to your benefit. And we integrate our services early on to help you expeditiously advance your asset through clinical and regulatory milestones, while ensuring the safety of study participants and your molecule's return on investment.
